{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:52:32Z","timestamp":1773251552454,"version":"3.50.1"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.pharmthera.2004.04.002","type":"journal-article","created":{"date-parts":[[2004,7,9]],"date-time":"2004-07-09T15:09:41Z","timestamp":1089385781000},"page":"177-193","source":"Crossref","is-referenced-by-count":176,"title":["The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile"],"prefix":"10.1016","volume":"102","author":[{"given":"Marinos C","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2004.04.002_BIB1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1994.tb00854.x","article-title":"Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy","volume":"139","author":"Abe","year":"1994","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB2","first-page":"157","article-title":"Intravenous immunoglobulin induced-nephropathy: a complication of IVIg therapy","volume":"11","author":"Ahsan","year":"1998","journal-title":"J Nephrol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB3","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1001\/archinte.154.17.1985","article-title":"Intravenous immunoglobulin-induced osmotic nephrosis","volume":"154","author":"Ahsan","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Downregulation of TGF-\u03b21 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1365-2249.1999.00757.x","article-title":"Administration of intravenous immunoglobulin (IVIg) in vivo downregulatory effects on the IL-1 system","volume":"115","author":"Ankrust","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0387-7604(93)90071-F","article-title":"The use of intravenous immunoglobulin in Miller-Fisher syndrome","volume":"15","author":"Arakawa","year":"1993","journal-title":"Brain Dev"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","article-title":"Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies","volume":"44","author":"Azulay","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin (IVIg) treatment on muscle weakness and calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB9","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB10","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI114387","article-title":"Mechanisms of therapeutic effect of high-dose intravenous immunoglobulin","volume":"84","author":"Basta","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-5728(96)00133-6","article-title":"Increased in vitro uptake of the complement C3b in the serum of patients with Guillain Barr\u00e9 syndrome, myasthenia gravis and dermatomyositis","volume":"71","author":"Basta","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB13","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1002\/art.11346","article-title":"Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-\u03b1 present in serum from patients with systemic lupus erythematosus","volume":"48","author":"Bayry","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO;2-N","article-title":"Complications of intravenous gammaglobulin in neuromuscular and other diseases","volume":"19","author":"Bertorini","year":"1996","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00915419","article-title":"Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies","volume":"7","author":"Bj\u00f6rkander","year":"1987","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0140-6736(93)90563-V","article-title":"Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations","volume":"341","author":"Blasczyk","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp.59.1.38","article-title":"Multifocal motor neuropathy with conduction block: a study of 24 patients","volume":"59","author":"Bouche","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.47.3.674","article-title":"Complications of intravenous immune globulin treatment in neurologic disease","volume":"47","author":"Brannagan","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barr\u00e9 syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM198602273140907","article-title":"Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia","volume":"314","author":"Burks","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB22","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/WNL.43.5.1034","article-title":"Human immune globulin infusion in Guillain-Barr\u00e9 syndrome: worsening during and after treatment","volume":"43","author":"Castro","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ana.410330303","article-title":"Multifocal motor neuropathy: response to human immune globulin","volume":"33","author":"Chaudhry","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","article-title":"A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy","volume":"249","author":"Comi","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJM199308193290820","article-title":"Recurrent migraine and intravenous immune globulin therapy","volume":"329","author":"Constantinescu","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/WNL.40.2.212","article-title":"High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy","volume":"40","author":"Cook","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-5728(02)00430-7","article-title":"Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FCgammaRII expression in patients with chronic inflammatory neuropathies","volume":"135","author":"Creange","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB31","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7326\/0003-4819-122-4-199502150-00021","article-title":"Aseptic meningitis and intravenous immunoglobulin","volume":"122","author":"Dalakas","year":"1995","journal-title":"Ann Intern Med"},{"issue":"S","key":"10.1016\/j.pharmthera.2004.04.002_BIB35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ana.410370703","article-title":"Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects","volume":"37","author":"Dalakas","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1212\/WNL.48.Suppl_5.64S","article-title":"Experience with IVIg in the treatment of patients with myasthenia gravis","volume":"48S","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB37","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immunoglobulin therapy for neurological diseases","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.7326\/0003-4819-127-12-199712150-00022","article-title":"Meningitis and skin reactions after intravenous immunoglobulin therapy","volume":"127","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB39","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1212\/WNL.51.6_Suppl_5.S37","article-title":"Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB40","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.6_Suppl_5.S2","article-title":"Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the Treatment of autoimmune neurologic diseases","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00019052-199908000-00006","article-title":"Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers","volume":"12","author":"Dalakas","year":"1999","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB42","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.10259","article-title":"Blockade of blocking antibodies in Guillain-Barr\u00e9 syndromes: \u201cunblocking\u201d the mystery of action of intravenous immunoglobulin","volume":"51","author":"Dalakas","year":"2002","journal-title":"Ann Neurol"},{"issue":"Suppl 6","key":"10.1016\/j.pharmthera.2004.04.002_BIB44","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.59.12_suppl_6.S13","article-title":"Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies","volume":"59","author":"Dalakas","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB45","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB46","series-title":"Intravenous Immunoglobulins in the Third Millennium","first-page":"37","article-title":"Witnessing the introduction and use of IVIg in neurology","author":"Dalakas","year":"2004"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB47","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.WNL.0000074394.15882.83","article-title":"Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record","volume":"60","author":"Dalakas","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB48","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB49","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archneur.1994.00540210031010","article-title":"Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy","volume":"51","author":"Dalakas","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB51","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB52","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion body, myositis with IVIg: a double-blind, placebo-control study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB53","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.55.10.1531","article-title":"The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome","volume":"55","author":"Dalakas","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB54","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB56","doi-asserted-by":"crossref","first-page":"11409","DOI":"10.1016\/S0021-9258(19)78139-3","article-title":"Cross linking of Fc receptor to surface immunoglobulin on B cells provides on inhibitory signal that closes the plasma membrane calcium channel","volume":"269","author":"Diegel","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB57","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1172\/JCI114483","article-title":"Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains anti-idiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies","volume":"85","author":"Dietrich","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB58","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB59","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ana.410350618","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study","volume":"35","author":"Dutch Guillain-Barr\u00e9 Syndrome Study Group","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB61","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB62","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJM199210013271416","article-title":"High-dose intravenous immune globulin and acute renal failure","volume":"327","author":"Ellie","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB63","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1212\/WNL.44.5.967","article-title":"Progression of multifocal motor demyelinating neuropathy during apparently successful treatment with human immunoglobulin","volume":"44","author":"Elliott","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB64","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(97)24050-X","article-title":"Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barr\u00e9 syndrome","volume":"350","author":"Farcas","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB65","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","article-title":"Efficiency of plasma exchange in Guillain-Barr\u00e9 syndrome: role of replacement fluids","volume":"22","author":"French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","year":"1987","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB67","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/brain\/120.9.1533","article-title":"Human immunoglobulin ameliorates rat experimental allergic neuritis","volume":"120","author":"Gabriel","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB68","series-title":"Intravenous Immunoglobulins in the Third Millennium","first-page":"203","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2004"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB69","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1474-4422(03)00264-3","article-title":"Immunotherapy in autoimmune neuromuscular disorders","volume":"2","author":"Gold","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB71","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome","volume":"35","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB72","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.410400414","article-title":"Acute motor axonal neuropathy: an antibody-mediated attack on axolemma","volume":"40","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB74","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02076702","article-title":"Hyperviscosity in HIV infected children: a potential hazard during intravenous immunoglobulin therapy","volume":"61","author":"Hague","year":"1990","journal-title":"Blut"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB75","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(97)12308-X","article-title":"Guillain-Barr\u00e9 syndrome","volume":"352","author":"Hahn","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB76","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","article-title":"Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB77","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/mus.880180203","article-title":"Immunopathogenesis and treatment of the Guillain-Barr\u00e9 syndrome\u2014Part II","volume":"18","author":"Hartung","year":"1995","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB80","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.48.3.695","article-title":"Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection","volume":"48","author":"Ho","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.48.3.695","article-title":"Patterns of clinical recovery in Guillain Barr\u00e9 Syndrome","volume":"48","author":"Ho","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB78","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB82","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1212\/WNL.51.6_Suppl_5.S30","article-title":"Intravenous immunoglobulin for the treatment of acquired myasthenia gravis","volume":"51","author":"Howard","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1090-3798(97)80004-9","article-title":"Intravenous immunoglobulin treatment in children with Guillain-Barr\u00e9 syndrome","volume":"1","author":"Kanra","year":"1997","journal-title":"Eur J Pediatr Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB86","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1172\/JCI118488","article-title":"Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use","volume":"97","author":"Kaveri","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB87","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/135245859700300211","article-title":"Modulation of autoimmune responses by intravenous immunoglobulin","volume":"3","author":"Kaveri","year":"1997","journal-title":"Mult Scler"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB88","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB89","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-065X.1994.tb00858.x","article-title":"V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin","volume":"139","author":"Kazatchkine","year":"1994","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB90","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0140-6736(05)78212-X","article-title":"Intravenous immunoglobulins and transforming growth factor b","volume":"351","author":"Kekow","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 6","key":"10.1016\/j.pharmthera.2004.04.002_BIB91","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1212\/WNL.59.12_suppl_6.S7","article-title":"Immune mechanisms in chronic inflammatory demyelinating neuropathy","volume":"59","author":"Kieseier","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB92","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","article-title":"Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases","volume":"20","author":"Koffman","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB93","series-title":"Intravenous Immunoglobulin in the Third Millennium","first-page":"181","article-title":"Clinical experience with intravenous immunoglobulin for treatment of pediatric Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","author":"Kornberg","year":"2004"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB94","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.410350217","article-title":"The clinical correlates of high-titer IgG anti-GM1 antibodies","volume":"35","author":"Kornberg","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB97","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1172\/JCI112530","article-title":"Comparison of intravenous gammaglobulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice","volume":"77","author":"Kurlander","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB98","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/WNL.51.6.1656","article-title":"Two patterns of clinical recovery in Guillain-Barr\u00e9 syndrome with IgG anti-GM1 antibody","volume":"51","author":"Kuwabara","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/jnnp.57.Suppl.46","article-title":"Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy","volume":"57S","author":"Leger","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB102","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410390121","article-title":"Intravenous y-globulin inhibits binding of anti-GMI to its target antigen","volume":"39","author":"Malik","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB103","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.89.8.3325","article-title":"Human autoantibodies reactive with synthetic autoantigens from T cell receptor V\u03b2 chain","volume":"89","author":"Marchalonis","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB104","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","article-title":"Immunoglobulin therapy in inflammatory myopathies","volume":"65","author":"Mastaglia","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","article-title":"Cost-utility analysis of intravenous immunoglobulin and polyradiculoneuropathies (CIDP)","volume":"10","author":"McCrone","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB106","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB107","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1212\/WNL.47.1.98","article-title":"Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up","volume":"47","author":"Nevo","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB108","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","article-title":"A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome","volume":"324","author":"Newburger","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB109","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0165-5728(01)00266-1","article-title":"Multifocal motor neuropathy","volume":"115","author":"Nobile-Orazio","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1212\/WNL.43.3_Part_1.537","article-title":"High-dose immunoglobulin therapy in multifocal motor neuropathy","volume":"43","author":"Nobile-Orazio","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB111","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomized trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB112","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB113","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ana.410380516","article-title":"Antiganglioside antibodies in Guillain Barr\u00e9 syndrome and their relationship to Campylobacter jejuni infection","volume":"38","author":"Rees","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB114","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0887-8994(96)00050-1","article-title":"Severe Guillain-Barr\u00e9 syndrome in childhood treated with human immune globulin","volume":"14","author":"Reisin","year":"1996","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/clin.1994.1091","article-title":"Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules","volume":"71","author":"Rigal","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"issue":"9","key":"10.1016\/j.pharmthera.2004.04.002_BIB116","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1567-5769(03)00134-6","article-title":"Comparison of the efficacy of IGIV-C, 10% (caprylate\/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial","volume":"3","author":"Roifman","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB117","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/(SICI)1097-4598(199810)21:10<1327::AID-MUS14>3.0.CO;2-Z","article-title":"Relapses in the Guillain-Barr\u00e9 syndrome after treatment with intravenous immune globulin or plasma exchange","volume":"21","author":"Romano","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB118","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.4049\/jimmunol.144.4.1387","article-title":"A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG","volume":"144","author":"Roux","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB119","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1097-4598(200103)24:3<311::AID-MUS1001>3.0.CO;2-A","article-title":"Clinical spectrum of chronic acquired demyelinating polyneuropathies","volume":"24","author":"Saperstein","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB121","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199412153312409","article-title":"Transmission of viral infections through intravenous immune globulin","volume":"331","author":"Schiff","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB122","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB123","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archneur.59.5.758","article-title":"Demyelinating neuropathy in diabetes mellitus","volume":"59","author":"Sharma","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB124","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1212\/WNL.42.1.257","article-title":"Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis","volume":"42","author":"Silbert","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB125","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/(SICI)1097-4598(199712)20:12<1569::AID-MUS12>3.0.CO;2-W","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults","volume":"20","author":"Simmons","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB127","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0022-510X(97)00292-X","article-title":"Intravenous immunoglobulin treatment of neurological autoimmune diseases","volume":"153","author":"Stangel","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB128","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1212\/WNL.44.6.1180","article-title":"Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis","volume":"44","author":"Steg","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB129","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1172\/JCI116862","article-title":"Binding of cytokines to pharmaceutically prepared human immunoglobulin","volume":"92","author":"Svenson","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB131","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1172\/JCI116240","article-title":"Intravenous immunoglobulin contains specific antibodies inhibitory of activation of T cells by staphylococcal toxin superantigens","volume":"91","author":"Takei","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB132","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0161-5890(88)90088-0","article-title":"Immunoglobulin G dimer: an idiotype-anti-idiotype complex","volume":"25","author":"Tankersley","year":"1988","journal-title":"Mol Immunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB133","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","article-title":"How long is IVIg effective in multifocal motor neuropathy?","volume":"62","author":"Terenghi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB134","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.4049\/jimmunol.137.10.3124","article-title":"Cooperativity between B lymphocytes membrane molecules: independent ligand occupancy and crosslinking of antigen receptors and Fc gamma receptors downregulates B lymphocyte function","volume":"137","author":"Uher","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB135","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","article-title":"Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study","volume":"59","author":"Van den Berg","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB136","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/brain\/121.3.421","article-title":"The long term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy","volume":"121","author":"Van den Berg","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB137","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/brain\/awf193","article-title":"Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment","volume":"125","author":"Van den Berg-Vos","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB138","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"326","author":"van der Meche","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB141","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/jnnp.57.Suppl.65","article-title":"Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis","volume":"57","author":"van Engelson","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry (Suppl)"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB142","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomized trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB143","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1993.tb03407.x","article-title":"Antibodies to the CD5 molecule in Normal Human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)","volume":"92","author":"Vassilev","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB144","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study","volume":"56","author":"Vermeulen","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB146","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/jnnp.64.2.242","article-title":"Risk factors for treatment related clinical fluctuations in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 study group","volume":"64","author":"Visser","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB147","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.46.1.250","article-title":"Reversible encephalopathy with cerebral vasospasm in a GBS patient treated with IV immunoglobulin","volume":"46","author":"Voltz","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB148","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB149","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1212\/WNL.51.6.1738","article-title":"Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma","volume":"51","author":"Weiss","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0165-5728(98)00247-1","article-title":"Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia","volume":"95","author":"Weiss","year":"1999","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB151","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB152","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB153","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1473-3099(01)00019-6","article-title":"Infectious origins of, and molecular mimicry in, Guillain-Barr\u00e9 and Fisher syndromes","volume":"1","author":"Yuki","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.pharmthera.2004.04.002_BIB154","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0022-510X(96)00053-6","article-title":"Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies","volume":"139","author":"Yuki","year":"1996","journal-title":"J Neurol Sci"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T23:45:44Z","timestamp":1682725544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725804000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0163725804000506"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2004.04.002","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}